生物科技公司Prothena Corporation plc近日宣布,对2026财年经营活动和投资活动产生的净现金使用额预期作出调整。根据最新预测,该公司预计全年净现金使用额将介于1800万至2300万美元区间。
此次更新反映了公司对研发管线推进及运营资金管理的动态评估。作为专注于神经退行性疾病创新疗法的企业,Prothena将持续优化资源分配以支持核心项目的临床开发。
生物科技公司Prothena Corporation plc近日宣布,对2026财年经营活动和投资活动产生的净现金使用额预期作出调整。根据最新预测,该公司预计全年净现金使用额将介于1800万至2300万美元区间。
此次更新反映了公司对研发管线推进及运营资金管理的动态评估。作为专注于神经退行性疾病创新疗法的企业,Prothena将持续优化资源分配以支持核心项目的临床开发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.